Daily Cardiology Research Analysis
Analyzed 120 papers and selected 3 impactful papers.
Summary
Three studies stand out today: an IPD meta-analysis across four pivotal AF trials shows non–vitamin K oral anticoagulants reduce rare but morbid systemic embolic events versus warfarin; a multicenter prospective study links cardiologist evaluation after peri-operative myocardial infarction/injury to markedly lower 1-year MACE and mortality; and a Circulation mechanistic study identifies a DAPK2–PKM2 Thr45 phosphorylation axis driving disturbed-flow atherogenesis, highlighting a new therapeutic target.
Research Themes
- Antithrombotic therapy optimization in atrial fibrillation beyond stroke prevention
- Perioperative cardiology co-management and outcomes
- Endothelial mechanotransduction mechanisms in atherogenesis
Selected Articles
1. Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin.
Across four pivotal AF trials (n=71,683), SEE occurred at ~0.13% per patient-year versus 1.25% for ischemic stroke. DOACs significantly reduced SEE compared with warfarin, and SEE carried mortality and morbidity comparable to ischemic stroke despite being less frequent.
Impact: This IPD meta-analysis clarifies the effect of DOACs on systemic embolism, an underrecognized yet morbid outcome in AF, strengthening the evidence base for DOACs beyond stroke prevention.
Clinical Implications: Supports preferential DOAC use over warfarin to mitigate SEE risk in AF, and highlights the need for vigilance and management pathways recognizing SEE’s high morbidity despite low incidence.
Key Findings
- SEE incidence was ~0.13% per patient-year versus 1.25% for ischemic stroke across 71,683 AF patients.
- DOACs significantly reduced SEE risk compared with warfarin.
- SEE patients experienced mortality and morbidity comparable to ischemic stroke despite lower frequency.
Methodological Strengths
- Individual patient data meta-analysis of four randomized trials
- Large sample size enabling precise estimates of rare events
Limitations
- Trials enrolled between 2005–2010; practice patterns and dosing may differ today
- SEE events were rare, which may limit subgroup analyses
Future Directions: Define SEE risk profiles and optimize anticoagulation strategies (including dosing and monitoring) to prevent SEE; evaluate DOAC effects on SEE in contemporary real-world cohorts.
BACKGROUND: Systemic embolic events (SEEs) are a serious but underrecognized complication of atrial fibrillation. Although non-vitamin K antagonist oral anticoagulants prevent ischemic stroke (IS), their efficacy in SEE and the clinical characteristics of patients who experience SEE remain poorly understood. METHODS: We analyzed individual patient data from 4 pivotal randomized trials enrolling patients between 2005 and 2010 comparing non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation. We characterized the incidence, clinical features, management, and outcomes of clinically overt SEE and compared results in these patients with patients who had an IS. RESULTS: Among 71 683 patients, 188 experienced SEE (26 with concurrent IS), yielding an annualized event rate of 0.13% per patient-year, compared with 1.25% per patient-year for IS (n=1797). Among 171 patients with SEE as their first event, median age was 75 years (interquartile range, 68-80), 49.7% were female, and mean±SD CHA
2. DAPK2 Regulates PKM2 Phosphorylation at Threonine 45 to Facilitate Disturbed Flow-Induced Atherosclerosis.
Using multi-omic discovery and biochemical mapping, the study shows DAPK2 is upregulated in oscillatory shear regions and directly phosphorylates PKM2 at Thr45, driving endothelial inflammatory activation under disturbed flow and promoting atherosclerosis.
Impact: Reveals a previously unrecognized mechanotransduction pathway linking disturbed flow to endothelial inflammation via DAPK2–PKM2, nominating a druggable target for atherosclerosis.
Clinical Implications: While preclinical, targeting DAPK2 or PKM2 Thr45 phosphorylation could modulate vascular inflammation at athero-prone sites, informing future anti-atherosclerotic therapies.
Key Findings
- DAPK2 expression is elevated in human and murine arterial regions exposed to oscillatory shear stress.
- DAPK2 binds PKM2 and phosphorylates it at threonine 45, identified via mass spectrometry and biochemical assays.
- DAPK2-driven PKM2 Thr45 phosphorylation orchestrates endothelial inflammatory responses to disturbed flow, promoting atherogenesis.
Methodological Strengths
- Integrated multi-omic discovery with targeted biochemical validation (mass spectrometry, co-IP, PLA)
- Use of human and murine vascular tissues with in vivo endothelial-specific modeling
Limitations
- Preclinical mechanistic study without clinical outcome validation
- Abstract truncation limits detail on in vivo effect sizes and KLF2-mediated regulation
Future Directions: Develop selective inhibitors/modulators of the DAPK2–PKM2 Thr45 axis; test efficacy and safety in relevant in vivo models and translational studies targeting athero-prone vascular regions.
BACKGROUND: Oscillatory shear stress (OSS), resulting from disturbed blood flow, is implicated in atherosclerotic plaque formation by incompletely understood mechanisms. This study aims to elucidate the involvement of death-associated protein kinase (DAPK) 2 in OSS-induced endothelial cell (EC) activation and atherosclerosis. METHODS: Publicly available resources, including genome-wide microarray, RNA sequencing, and single-cell RNA sequencing, were utilized to identify key OSS-sensitive regulatory factors. Techniques such as mass spectrometry, immunoprecipitation, proximity ligation assay, and RNA sequencing were employed to identify pyruvate kinase M2 (PKM2) as the binding protein of DAPK2 and determine the specific site of PKM2 phosphorylation by DAPK2. To assess the role of Dapk2 in vivo, EC-specific RESULTS: DAPK2 expression was elevated in OSS-exposed regions of human and murine arteries. Mechanistically, Krüppel-like factor 2 (KLF2) suppressed CONCLUSIONS: DAPK2-driven phosphorylation of PKM2 at threonine 45 orchestrates endothelial inflammatory responses to disturbed flow, identifying a novel mechanistic axis and potential therapeutic target in atherosclerosis.
3. Peri-operative myocardial infarction/injury after non-cardiac surgery: association between cardiologist evaluation and outcomes.
In a multicenter prospective cohort of 1,048 PMI cases, post-operative cardiologist evaluation was associated with significantly lower 1-year MACE (aHR 0.54) and all-cause mortality (aHR 0.65). Evaluation correlated with more cardiac imaging and intensified antithrombotic/lipid-lowering therapy.
Impact: Provides real-world evidence that structured cardiology co-management after PMI may improve outcomes, supporting implementation of perioperative surveillance-and-response pathways.
Clinical Implications: Health systems should consider routine cardiology evaluation for PMI flagged by surveillance, with protocols for imaging and guideline-directed therapies to reduce downstream MACE and mortality.
Key Findings
- Among 1,048 PMI patients, cardiologist evaluation was associated with lower 1-year MACE (adjusted HR 0.54, P=.001).
- Cardiologist evaluation was also associated with reduced all-cause mortality at 365 days (adjusted HR 0.65, P=.037).
- Evaluated patients more frequently underwent non-invasive cardiac imaging and received dual antiplatelet therapy and statins.
Methodological Strengths
- Prospective multicenter design with predefined surveillance-and-response program
- Natural variation in availability created a quasi-experimental comparison; adjusted Cox models and sensitivity analyses
Limitations
- Non-randomized exposure may leave residual confounding despite adjustment
- Findings depend on local program structure and may require adaptation for generalizability
Future Directions: Cluster-randomized or stepped-wedge trials of perioperative cardiology co-management; standardized care pathways integrating imaging and GDMT to validate causality and scalability.
BACKGROUND AND AIMS: Peri-operative myocardial infarction/injury (PMI) is a common cardiac complication following non-cardiac surgery. It remains unclear whether involvement of cardiologists in the management of patients developing PMI improves outcomes. METHODS: This multicentre, prospective study included high-risk patients undergoing non-cardiac surgery, eligible for the institutional PMI active surveillance and response programme. Due to staffing constraints, cardiologist evaluation of patients with PMI was inconsistently available on weekends, on public holidays, or when care for more urgent patients had to be prioritized, allowing a comparison between patients receiving cardiologist evaluation and those who did not. The primary endpoint was major adverse cardiac events, defined as a composite of cardiovascular death, myocardial infarction, acute heart failure, and life-threatening arrhythmia at 365 days. The secondary endpoint was all-cause death at 365 days. Cox proportional hazards models were used to evaluate the association between cardiologist evaluation and outcomes. RESULTS: Among 14 294 patients, 1048 developed PMI and were eligible for this analysis, of whom 614 patients (58.6%) received post-operative cardiologist evaluation. Baseline characteristics were similar between groups. After adjustment, cardiologist evaluation was independently associated with lower risk of major adverse cardiac events (adjusted hazard ratio .54, P = .001) and all-cause death (adjusted hazard ratio .65, P = .037) at 365 days. Sensitivity analyses confirmed these findings. Patients receiving cardiology evaluation were more likely to undergo non-invasive cardiac imaging and to receive dual antiplatelet and statin therapy. CONCLUSIONS: Cardiologist evaluation of patients with PMI following major non-cardiac surgery was associated with a reduced risk of major adverse cardiac events and all-cause mortality at 365 days after surgery, suggesting that interdisciplinary management may improve post-operative outcomes.